# US 2024/0199625 A1 · Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199625 A1
- Document ID: US20240199625A1
- Status: Published application
- Kind: A1
- Application number: 18/552,649
- Filed: 2021-11-10
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: Hangzhou Apeloa Medicine Research Institute Co., Ltd.; Apeloa Pharmaceutical Co., Ltd.
- Applicants: Hangzhou Apeloa Medicine Research Institute Co., Ltd.; Apeloa Pharmaceutical Co., Ltd.
- Inventors: Weiqiang ZHAN; Zhanguo WANG; Weiliang CHEN; Yaofeng JIN; Jianhua LV; Sai LIANG; Xuejie GUO; Fangmeng ZHU
- Web page: https://patentgrep.com/patent/US20240199625A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- C07D 471/04: Ortho-condensed systems
- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention belongs to the field of medicinal chemistry, specifically relates to bicyclic heterocycles as FGFR4 inhibitors, including the pharmaceutical composition and preparation, and applications thereof. In particular, the present invention provides a compound having a structure of formula (I), which may act as an FGFR4 inhibitor to prevent and/or treat the diseases at least partially mediated by FGFR4 (e.g., cancer).

## Claims

### Claim 1

A compound of formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof,
wherein
X is CH or N;
Y is two H or one O;
Z is C(R6)2 or N(R6);
m is 0 or 1;
L is —C(R7)2— or
n is 0, 1, or 2;
each R1 is independently C1-3 alkyl or C1-3 haloalkyl;
R2 and R3 are independently hydrogen, halogen, C1-3 alkyl, C1-3 haloalkyl, cyano, or C1-3 alkoxy;
R4 is hydrogen, C1-6 alkyl, or C6-10 aryl;
R5 is hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C1-6 alkyl, C2-8 alkenyl, C6-10 aryl, C1-8 alkyl amino, bis (C2-8 alkyl) amino, C2-8 alkynyl, C1-8 haloalkyl, or C3-8 cycloalkyl;
each R6 is independently hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C6-10 aryl, C6-10 aryl with substituents, C3-10 cycloalkyl, 5 to 10 membered heteroaryl, or 4 to 10 membered heterocycloalkyl; wherein each 5 to 10 membered heteroaryl or 4 to 10 membered heterocycloalkyl independently contains 1 to 3 cyclic heteroatoms, the heteroatoms are N, O or S independently;
or two R6 and the carbon atoms connected thereto together form C3-8 cycloalkyl or 4 to 10 membered heterocycloalkyl; wherein 4 to 10 membered heterocycloalkyl contains 1 to 3 cyclic heteroatoms, the heteroatoms are N, O or S; each C3-8 cycloalkyl or 4 to 10 membered heterocycloalkyl is optionally substituted with 1 to 4 substituents, the substituents are independently halogen, cyano, hydroxyl, amino, C1-8 carboxyamide, C1-8 carboxylacyl, C1-8 alkyl, or C1-8 alkoxy;
each R7 is independently hydrogen, halogen, amino, cyano, C1-8 alkyl, C1-8 alkyl with substituent, C1-8 alkoxy, C1-8 alkoxy with substituents, C1-8 alkyl amino, bis (C2-8 alkyl) amino, C2-8 alkenyl, C2-8 alkenyl with substituents, C2-8 alkynyl, C2-8 alkynyl with substituents, C6-10 aryl, C6-10 aryl with substituents, C3-8 cycloalkyl, C3-8 cycloalkyl with substituents, 3 to 10 membered heterocycloalkyl, 3 to 10 membered heterocycloalkyl with substituents, 5 to 10 membered heteroaryl, or 5 to 10 membered heteroaryl with substituents; wherein each 3 to 10 membered heterocycloalkyl or 5 to 10 membered heteroaryl independently contains 1 to 3 cyclic heteroatoms, the heteroatoms are N, O or S independently.

### Claim 2 (depends on 1)

The compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, wherein the compound has a structure of formula (II),
wherein X, Y, Z, m, L, R2 and R3 are as defined in claim 1;
or,
wherein the compound has a structure of formula (III),
wherein Z, m, L, R2 and R3 are as defined in claim 1;
or,
wherein the compound has a structure of formula (III-1) or formula (III-2),
wherein Z, L, R2 and R3 are as defined in claim 1;
or, the compound of formula (III-1) has a structure of formula (III-1-1),
wherein R2, R3, and R6 are as defined in claim 1, R7 is hydrogen, C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl, wherein each C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl is optionally substituted with at least one R8, each R8 is independently hydrogen, C1-4 alkyl, morpholinyl, bridged-ring morpholinyl, piperazinyl, piperazinyl with substituents, bridge-ring piperazinyl, bridged-ring piperazinyl with substituents, oxetalkyl, or oxetalkyl with the substituents, the substituent is C1-4 alkyl;
or, R2, R3, and R6 are as defined in claim 1, R7 is hydrogen, C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl, wherein each C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl is optionally substituted with at least one R8, each R8 is independently hydrogen, morpholinyl, bridged-ring morpholinyl, piperazinyl, piperazinyl with substituents, bridge-ring piperazinyl, bridged-ring piperazinyl with substituents, oxetalkyl, or oxetalkyl with substituents, the substituent is C1-4 alkyl;
or, R2, R3, and R6 are as defined in claim 1, R7 is one of the following fragments
or, the compound of formula (III-2) has a structure of formula (III-2-1) or formula (III-2-2),
wherein R2, R3, and R6 are as defined in claim 1;
or,
wherein the compound has a structure of formula (IV),
wherein Z, m, L, R2 and R3 are as defined in claim 1;
or,
wherein the compound has a structure of formula (IV-1) or formula (IV-2),
wherein Z, L, R2 and R3 are as defined in claim 1;
or, the compound of formula (IV-1) has a structure of formula (IV-1-1),
wherein R2, R3, and R6 are as defined in claim 1, R7 is hydrogen, C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl, wherein each C1-4 alkyl, piperazinyl, piperidinyl, or morpholinoyl is optionally substituted with at least one R8, each R8 is independently hydrogen, morpholinyl, bridged-ring morpholinyl, piperazinyl, piperazinyl with substituents, bridge-ring piperazinyl, bridged-ring piperazinyl with substituents, oxetalkyl, or oxetalkyl with substituents, the substituent is C1-4 alkyl;
or, R2, R3, and R6 are as defined in claim 1, R7 is one of the following fragments
or, the compound of formula (IV-2) has a structure of formula (IV-2-1) or formula (IV-2-2),
wherein R2, R3, and R6 in formula (IV-2-1) are as defined in claim 1, and R7 is hydrogen, C1-4 alkyl, or
R2, R3, and R6 in formula (IV-2-2) are as defined in claim 1.

### Claim at position 3

3-6. (canceled)

### Claim 7

A compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof,

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof.

### Claim 9 (depends on 1)

A pharmaceutical preparation comprising the compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, or the pharmaceutical preparation is selected from the group consisting of a tablet, a capsule, an injectable, a granule, a powder, a suppository, a pill, a gel, a pulvis, an oral solution, an inhalant, a suspension, and a dry suspension.

### Claim at position 7

10-11. (canceled)

### Claim 12 (depends on 1)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising the following steps:
administering a prophylactically and/or therapeutically amount of the compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 13 (depends on 1)

A method for preventing and/or treating cancer, comprising the following steps:
administering a prophylactically and/or therapeutically amount of the compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof and at least one additional cancer therapeutic agent, to a patient in need thereof;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 14 (depends on 1)

A drug combination comprising the compound according to claim 1, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, and at least one additional cancer therapeutic agent.

### Claim 15 (depends on 7)

A pharmaceutical composition comprising the compound according to claim 7, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof.

### Claim 16 (depends on 7)

A pharmaceutical preparation comprising the compound according to claim 7, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, wherein the pharmaceutical preparation is selected from the group consisting of a tablet, a capsule, an injectable, a granule, a powder, a suppository, a pill, a gel, a pulvis, an oral solution, an inhalant, a suspension, and a dry suspension.

### Claim 17 (depends on 8)

A pharmaceutical preparation comprising the pharmaceutical composition according to claim 8, wherein the pharmaceutical preparation is selected from the group consisting of a tablet, a capsule, an injectable, a granule, a powder, a suppository, a pill, a gel, a pulvis, an oral solution, an inhalant, a suspension, and a dry suspension.

### Claim 18 (depends on 15)

A pharmaceutical preparation comprising the pharmaceutical composition according to claim 15, wherein the pharmaceutical preparation is selected from the group consisting of a tablet, a capsule, an injectable, a granule, a powder, a suppository, a pill, a gel, a pulvis, an oral solution, an inhalant, a suspension, and a dry suspension.

### Claim 19 (depends on 7)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the compound according to claim 7, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 20 (depends on 8)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical composition according to claim 8 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 21 (depends on 15)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical composition according to claim 15 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 22 (depends on 9)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical preparation according to claim 9 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 23 (depends on 16)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical preparation according to claim 16 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 24 (depends on 17)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical preparation according to claim 17 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 25 (depends on 18)

A method for preventing and/or treating a disease at least partially mediated by FGFR4, comprising:
administering a prophylactically and/or therapeutically amount of the pharmaceutical preparation according to claim 18 to a patient in need thereof;
wherein the disease at least partially mediated by FGFR4 is cancer;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.

### Claim 26 (depends on 7)

A method for preventing and/or treating cancer, comprising:
administering a prophylactically and/or therapeutically amount of the compound according to claim 7, or the pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, chelate, non-covalent complex, or prodrug thereof, and at least one additional cancer therapeutic agent, to a patient in need thereof;
wherein the cancer is selected from the group consisting of hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin's lymphoma, Waldenstrom macroglobulinemia, hairy cell lymphoma, Burket lymphoma, glioblastoma, melanoma, mesothelioma, neuroblastoma, testicular cancer, squamous cell carcinoma, glioblastoma, and rhabdomyosarcoma.
